Accord’s Canada business operation was established in 2007 and is based out of Montreal, with regional presence in Toronto and research facility in Quebec City.
Accord continues to expand its commercial operations in Canada to promote, market and distribute its large and expanding global product portfolio.
Accord is striving to supply and make available high quality and yet affordable medicines to the Canadian healthcare sector.
Accord’s current Canada portfolio consists of 40 approved products and 14 product submissions awaiting approval from Health Canada. Our products are available in a multitude of different formats including Tablets (standard, film-coated, effervescent, sustained release), Capsules and Injectables (powder and solution vials, ampoules). Our current product portfolio is focused on multiple therapeutic segments such as Oncology & Supportive Therapies, Cardio-Vascular, Neurology and Anti-Diabetics.
Although a relative newcomer to Canada’s market, Accord is led by a dedicated team of longstanding professionals with a history of introducing customer inspired products, services and solutions which became benchmarks within the Canadian hospital market. Our highly experienced team is focused on serving both the hospital and retail sector with a growing pipeline of oncology injectable and oral solids
Accord Healthcare Canada
Michel Charbonneau has more than 30 years of experience in the pharmaceutical industry. During this period of time he held various managerial and executive positions within large pharmaceutical companies such as Glaxo Canada, Ross Laboratories, and Lederle in addition to worldwide and Quebec-based generic manufacturers such as Mayne Pharma, Uman pharma Canada, and Omega Laboratories.
During the course of his career Michel has gained extensive experience in the fields of strategic planning, marketing and sales, reimbursement policies, product line extensions, tenders, in-licensing and distribution agreements. Within Mayne Pharma Canada, Michel developed a keen interest and established a solid track record in the field of oncology. During his tenure he developed and implemented a strategic business plan which enabled the company to become the country’s leading generic oncology supplier.
Michel is a business graduate from l’Université du Québec à Montréal. He is the recipient of the Quebecor Media HEC Prize for outstanding salesmanship and the West-Island Chamber of Commerce Business Accolades Award.
We are acutely aware of the importance of uninterrupted supply of medication. Accord has 2 cGMP approved manufacturing facilities, which were successfully audited by USFDA and the MHRA. As part of our Risk Mitigation Plan, this redundancy provides us with the capability to manufacture at an alternate site in the event one site encounter any unforeseen manufacturing issues.
When possible, Accord strives to secure two API sources to supply manufacturing sites. Having two sources of API ensures an uninterrupted supply of medication when there is a shortage of one of the API sources With a global batch capacity and API sourcing, Accord has a solid Risk Mitigation Plan to maintain a constant supply of product in the Canadian market.
Accord is committed to putting user safety at the heart of our offering. We are a dynamic company unencumbered by past practice with a refreshing way of adding innovative features to our concepts and products with one goal in mind; delivering safe and efficacious pharmaceuticals to all users
Data Matrix is a relatively recent 2- dimensional barcode development. This code has a high data capacity, variable sizing capabilities and ability to withstand harsh environments. It is most commonly used for product identification and batch tracking of pharmaceuticals. Several organizations have recommended the use of Data Matrix due to the advantages it offers, such as:
• Improved Data Accuracy
• Faster Data Input and Handling
• Cost Benefit
Differentiating itself from other companies in the sector, Accord is able to bring this advantageous product labeling due to its highly advanced technology at our manufacturing facilities and product packing site.
The risks associated with manipulating cytotoxic products are numerous. Processes have to be in place to minimize surface residue, spillage from damage vials, breakage of vials and unsafe handling practice.
Accord recognizes that we need to employ both Preventative and Protective measures in a systematic way to prevent occupational exposure.
PharmaShield® is a system consisting on a superficial plastic sheathing around the vial, going from the reinforced non- PVC base to the vial seal. It acts as a protective barrier against potential cytotoxic surface residue.
After filling with a validated decontamination process, vials are labeled and fitted with a non-PVC foot and a transparent plastic sheath. This protective measure is decreasing contamination risk and increasing the vial’s resistance to breakage. It aids in containing spills from damaged vials. Finally, transparency provides easy inspection.
Unit-dose packaging with barcode:
With the goal of reducing the workload for pharmacists and pharmacy technicians by eliminating the additional step of cutting blisters as well as minimizing exposure to cytotoxic medications, Accord has developed and offers products such as Capecitabine in unidose blister pack with barcoding. This provides the healthcare professional with a safer package with the relevant product information on each one of the unidose from the blister packaging
Some of the benefits for hospital staff are:
Cross-perforated blisters offer a cost-effective and practical method of delivering unit dose packaging.
Improves hospital pharmacy storage of products.
Dispensing errors can be reduced since key information of the product is printed in every unit dose removable from the blister.
With this feature, pharmacist can easily scan the product information, favoring traceability and product control.